Innate Pharma reports positive Phase I/II trial data of monalizumab for advanced gynecologic malignancies

French clinical-stage biotechnology company Innate Pharma has reported positive data from its dose-ranging part of a Phase I/II trial of monalizumab to treat advanced gynecologic malignancies.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news